Literature DB >> 28232443

Genome Sequence of Novel Human Parechovirus Type 17.

Sindy Böttcher1, Patrick E Obermeier2, Sabine Diedrich2, Yolande Kaboré3, Rossella D'Alfonso3,4, Herbert Pfister5, Rolf Kaiser5, Veronica Di Cristanziano5.   

Abstract

Human parechoviruses (HPeV) circulate worldwide, causing a broad variety of symptoms, preferentially in early childhood. We report here the nearly complete genome sequence of a novel HPeV type, consisting of 7,062 nucleotides and encoding 2,179 amino acids. M36/CI/2014 was taxonomically classified as HPeV-17 by the picornavirus study group.
Copyright © 2017 Böttcher et al.

Entities:  

Year:  2017        PMID: 28232443      PMCID: PMC5323622          DOI: 10.1128/genomeA.01649-16

Source DB:  PubMed          Journal:  Genome Announc


GENOME ANNOUNCEMENT

Human parechoviruses (HPeVs) are small nonenveloped single-stranded RNA viruses belonging to the genus Parechovirus within the family Picornaviridae. The genomes are of positive polarity and comprise ~7,400 nucleotides (nt), including an open reading frame flanked by a 5′ and 3′ untranslated region (UTR). The polyprotein is cleaved by viral proteases into 10 structural and nonstructural viral proteins. Currently, 16 different types of HPeV have been designated based on the VP1 capsid protein sequence (1) (http://www.picornaviridae.com). Moreover, one new type has been proposed that did not cluster with any of the 16 types (2). HPeVs are associated with a broad spectrum of diseases, including gastroenteritis, respiratory diseases, meningitis/encephalitis, acute flaccid paralysis, and neonatal sepsis (3). Nevertheless, the majority of subjects with HPeV infections may remain asymptomatic (4). We have recently reported a hitherto-unassigned HPeV strain (M36/CI/2014) that was identified in a stool sample from a healthy 9-month-old female from Côte d’Ivoire (5). To further analyze this strain, we have amplified and sequenced nearly the entire genome. Based on parechovirus sequences available in GenBank, primers targeting the 5′ UTR (6) and 3Dpol region were used. The nearly entire genome was amplified using the PrimeScript one-step reverse transcription-PCR (RT-PCR) kit (TaKaRa Bio, Inc., Nojihigashi, Japan), and the 3′ UTR was amplified by one-step RT-PCR using 3′ rapid amplification of cDNA ends (3′RACE). Amplification of the complete 5′ UTR failed by using different 5′RACE kits. Therefore, 275 nt of the 5′ UTR of the genome is missing compared to the HPeV-1 prototype Harris (accession no. L02971). Sequencing was performed using a primer walking method directly on the PCR products after ExoSAP (Affymetrix, Santa Clara, CA, USA) treatment using BigDye Terminator 3.1 (Applied Biosytems, Foster City, CA, USA). The nearly entire genome of M36/CI/2014 consists of 7,062 nt, excluding the 3′-poly(A) tail. It contains 433 nt of the 5′ UTR, an open reading frame (ORF) that is 6,540 nt in length encoding 2,179 amino acids (aa), and a 3′ UTR of 89 nt. BLAST search of the complete genome sequence revealed low nucleotide identity (79 to 82%) to HPeV reference genomes available in GenBank (HPeV-1, accession no. L02971; HPeV-2, accession no. AF055846; HPeV-3, accession no. AB084913; HPeV-4, accession no. DQ315670; HPeV-5, accession no. HQ696576; HPeV-6, accession no. HQ696577; HPeV-7, accession no. EU556224; and HPeV-8, accession no. EU716175). Although one BLAST hit reached 86% (accession no. GQ183020), phylogenetic analysis using the complete genome of M36/CI/2014 and 30 other HPeV genomes available in GenBank clearly showed that M36/CI/2014 is distinct from the known HPeV types.

Accession number(s).

The virus genome sequence described here has been deposited in the GenBank database under the strain name M36/CI/2014 under the GenBank accession no. KT319121.
  6 in total

1.  Human parechoviruses are frequently detected in stool of healthy Finnish children.

Authors:  Pekka Kolehmainen; Sami Oikarinen; Marjaleena Koskiniemi; Olli Simell; Jorma Ilonen; Mikael Knip; Heikki Hyöty; Sisko Tauriainen
Journal:  J Clin Virol       Date:  2012-03-08       Impact factor: 3.168

2.  Parechovirus typing in clinical specimens by nested or semi-nested PCR coupled with sequencing.

Authors:  W Allan Nix; Kaija Maher; Mark A Pallansch; M Steven Oberste
Journal:  J Clin Virol       Date:  2010-05-15       Impact factor: 3.168

3.  Detection and characterization of a novel human parechovirus genotype in Thailand.

Authors:  Watchaporn Chuchaona; Pattara Khamrin; Arpaporn Yodmeeklin; Wilaiporn Saikruang; Tipachan Kongsricharoern; Nuthapong Ukarapol; Shoko Okitsu; Satoshi Hayakawa; Hiroshi Ushijima; Niwat Maneekarn
Journal:  Infect Genet Evol       Date:  2015-02-11       Impact factor: 3.342

4.  Detection and characterization of enteroviruses and parechoviruses in healthy people living in the South of Côte d'Ivoire.

Authors:  Veronica Di Cristanziano; Di Cristanziano Veronica; Sindy Böttcher; Böttcher Sindy; Sabine Diedrich; Diedrich Sabine; Monika Timmen-Wego; Timmen-Wego Monika; Elena Knops; Knops Elena; Nadine Lübke; Lübke Nadine; Rolf Kaiser; Kaiser Rolf; Herbert Pfister; Pfister Herbert; Yolande Kaboré; Kaboré Yolande; Rossella D'Alfonso; D'Alfonso Rossella
Journal:  J Clin Virol       Date:  2015-08-05       Impact factor: 3.168

5.  Human parechovirus infections in Dutch children and the association between serotype and disease severity.

Authors:  K S M Benschop; J Schinkel; R P Minnaar; D Pajkrt; L Spanjerberg; H C Kraakman; B Berkhout; H L Zaaijer; M G H M Beld; K C Wolthers
Journal:  Clin Infect Dis       Date:  2005-12-12       Impact factor: 9.079

6.  Epidemiology and clinical associations of human parechovirus respiratory infections.

Authors:  H Harvala; I Robertson; E C McWilliam Leitch; K Benschop; K C Wolthers; K Templeton; P Simmonds
Journal:  J Clin Microbiol       Date:  2008-08-27       Impact factor: 5.948

  6 in total
  1 in total

Review 1.  Parechovirus A Pathogenesis and the Enigma of Genotype A-3.

Authors:  Adithya Sridhar; Eveliina Karelehto; Lieke Brouwer; Dasja Pajkrt; Katja C Wolthers
Journal:  Viruses       Date:  2019-11-14       Impact factor: 5.048

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.